作者
Beatriz Rosales-Rodríguez,Juan Carlos Núñez-Enríquez,Ana Claudia Velázquez‐Wong,Carolina González-Torres,Javier Gaytán-Cervantes,Elva Jiménez‐Hernández,Jorge Alfonso Martín‐Trejo,María de los Ángeles del Campo-Martínez,Aurora Medina‐Sansón,Janet Flores‐Lujano,Luz Victoria Flores‐Villegas,José Gabriel Peñaloza‐González,José Refugio Torres‐Nava,Rosa Martha Espinosa‐Elizondo,Raquel Amador‐Sánchez,María Raquel Miranda-Madrazo,Jessica Denise Santillán-Juárez,María Luisa Pérez‐Saldivar,Alma Gurrola-Silva,Darío Orozco-Ruiz,Karina Anastacia Solís‐Labastida,Martha Margarita Velázquez‐Aviña,David Aldebarán Duarte-Rodríguez,Minerva Mata‐Rocha,Omar Alejandro Sepúlveda‐Robles,Mónica Ortiz-Maganda,Carolina Bekker-Méndez,Silvia Jiménez‐Morales,Juan Manuel Mejía‐Aranguré,Haydeé Rosas‐Vargas
摘要
Refining risk stratification to avoid very early relapses (VER) in Mexican patients with B-lineage acute lymphoblastic leukemia (B-ALL) could lead to better survival rates in our population. The purpose of this study was to investigate the association between the United Kingdom ALL (UKALL)-CNA classifier and VER risk in Mexican patients with childhood B-ALL. A nested case-control study of 25 cases with VER and 38 frequency-matched controls without relapse was conducted within the MIGICCL study cohort. They were grouped into the categories of the UKALL-CNA risk classifier (good [reference], intermediate and poor), according to the results obtained by multiplex ligation dependent probe amplification. Overall and disease-free survival (DFS) were estimated using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards analyses were conducted. The CDKN2A/B genes were most frequently deleted in the group with relapse. According to UKALL-CNA classifier, 33 (52.4%) patients were classified as good, 21 (33.3%) intermediate and 9 (14.3%) poor-risk B-ALL. The intermediate and poor risk groups were associated with an increased risk of VER (HR = 4.94, 95% CI = 1.87–13.07 and HR = 7.42, 95% CI = 2.37–23.26, respectively) in comparison to the good-risk patients. After adjusting by NCI risk classification and chemotherapy scheme in a multivariate model, the risks remained significant. Our data support the clinical utility of profiling CNAs to potentially refine current risk stratification strategies of patients with B-ALL.